# Rockwell Medical, Inc.: financial statements, quarterly

RMTI · Nasdaq · CIK 1041024 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/rmti.md) · [Financials](/companies/rmti/financials.md) · [Filings](/companies/rmti/filings.md) · [Insiders](/companies/rmti/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/rmti/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [23.8](/filings/0001628280-24-046839.md) | [22.1 d](/filings/0001628280-25-013983.md) | [22.7](/filings/0001628280-25-024434.md) | [25.8](/filings/0001041024-25-000011.md) | [28.3](/filings/0001628280-25-051290.md) | [24.7 d](/filings/0001628280-26-021186.md) | [18.9](/filings/0001628280-26-031663.md) | [16.1](/filings/0001628280-26-056461.md) | [15.9](/filings/0001628280-25-051290.md) | [18.3 d](/filings/0001628280-26-021186.md) | [17.3](/filings/0001628280-26-031663.md) | [17.8](/filings/0001628280-26-056461.md) |
| Cost of revenue | $m | [21.6](/filings/0001628280-24-046839.md) | [19.2 d](/filings/0001628280-25-013983.md) | [19.6](/filings/0001628280-25-024434.md) | [21.3](/filings/0001041024-25-000011.md) | [22.1](/filings/0001628280-25-051290.md) | [21.0 d](/filings/0001628280-26-021186.md) | [15.9](/filings/0001628280-26-031663.md) | [13.6](/filings/0001628280-26-056461.md) | [13.7](/filings/0001628280-25-051290.md) | [14.5 d](/filings/0001628280-26-021186.md) | [14.4](/filings/0001628280-26-031663.md) | [14.5](/filings/0001628280-26-056461.md) |
| Gross profit | $m | [2.2](/filings/0001628280-24-046839.md) | [2.9 d](/filings/0001628280-25-013983.md) | [3.1](/filings/0001628280-25-024434.md) | [4.6](/filings/0001041024-25-000011.md) | [6.2](/filings/0001628280-25-051290.md) | [3.6 d](/filings/0001628280-26-021186.md) | [3.0](/filings/0001628280-26-031663.md) | [2.5](/filings/0001628280-26-056461.md) | [2.3](/filings/0001628280-25-051290.md) | [3.9 d](/filings/0001628280-26-021186.md) | [2.9](/filings/0001628280-26-031663.md) | [3.2](/filings/0001628280-26-056461.md) |
| Research and development | $m | [0.5](/filings/0001628280-24-046839.md) | [0.2 d](/filings/0001628280-25-013983.md) | [0.0](/filings/0001628280-25-024434.md) | [0.0](/filings/0001041024-25-000011.md) | [0.0](/filings/0001628280-25-051290.md) | [0.0 d](/filings/0001628280-26-021186.md) | [0.0](/filings/0001628280-25-024434.md) | [0.0](/filings/0001628280-26-056461.md) | [0.0](/filings/0001628280-25-051290.md) | [0.0 d](/filings/0001628280-26-021186.md) | not reported | [0.0](/filings/0001628280-26-056461.md) |
| Selling, general and administrative | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(1.7)](/filings/0001628280-24-046839.md) | [(0.5) d](/filings/0001628280-25-013983.md) | [(1.3)](/filings/0001628280-25-024434.md) | [0.5](/filings/0001041024-25-000011.md) | [1.9](/filings/0001628280-25-051290.md) | [(0.5) d](/filings/0001628280-26-021186.md) | [(1.4)](/filings/0001628280-26-031663.md) | [(1.3)](/filings/0001628280-26-056461.md) | [(1.6)](/filings/0001628280-25-051290.md) | [(0.4) d](/filings/0001628280-26-021186.md) | [(1.5)](/filings/0001628280-26-031663.md) | [(1.1)](/filings/0001628280-26-056461.md) |
| Interest expense | $m | [0.4](/filings/0001628280-23-038781.md) | [1.1 d](/filings/0001628280-24-012572.md) | [0.4](/filings/0001628280-24-023056.md) | [0.2](/filings/0001041024-25-000011.md) | [0.3](/filings/0001628280-25-051290.md) | [0.3 d](/filings/0001628280-26-021186.md) | [0.3](/filings/0001628280-26-031663.md) | [0.3](/filings/0001628280-26-056461.md) | [0.3](/filings/0001628280-25-051290.md) | [0.3 d](/filings/0001628280-26-021186.md) | [0.3](/filings/0001628280-26-031663.md) | [0.3](/filings/0001628280-26-056461.md) |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(1.9)](/filings/0001628280-24-046839.md) | [(1.5) d](/filings/0001628280-25-013983.md) | [(1.7)](/filings/0001628280-25-051290.md) | [0.3](/filings/0001628280-25-051290.md) | [1.7](/filings/0001628280-25-051290.md) | [(0.8) d](/filings/0001628280-26-021186.md) | [(1.5)](/filings/0001628280-26-056461.md) | [(1.5)](/filings/0001628280-26-056461.md) | [(1.8)](/filings/0001628280-25-051290.md) | [(0.6) d](/filings/0001628280-26-021186.md) | [(1.6)](/filings/0001628280-26-056461.md) | [(1.2)](/filings/0001628280-26-056461.md) |
| Diluted EPS | $ per share | [(0.07)](/filings/0001628280-24-046839.md) | not reported | [(0.06)](/filings/0001628280-25-024434.md) | [0.01](/filings/0001041024-25-000011.md) | [0.04](/filings/0001628280-25-051290.md) | not reported | [(0.04)](/filings/0001628280-26-031663.md) | [(0.05)](/filings/0001041024-25-000011.md) | [(0.05)](/filings/0001628280-25-051290.md) | not reported | [(0.04)](/filings/0001628280-26-031663.md) | not reported |
| Basic EPS | $ per share | [(0.07)](/filings/0001628280-24-046839.md) | not reported | [(0.06)](/filings/0001628280-25-024434.md) | [0.01](/filings/0001041024-25-000011.md) | [0.05](/filings/0001628280-25-051290.md) | not reported | [(0.04)](/filings/0001628280-26-031663.md) | [(0.48)](/filings/0001628280-26-056461.md) | [(0.05)](/filings/0001628280-25-051290.md) | not reported | [(0.04)](/filings/0001628280-26-031663.md) | [(0.34)](/filings/0001628280-26-056461.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [7.8](/filings/0001628280-23-038781.md) | [9.0](/filings/0001628280-25-013983.md) | [6.6](/filings/0001628280-24-023056.md) | [11.9](/filings/0001628280-24-035859.md) | [12.3](/filings/0001628280-24-046839.md) | [15.7](/filings/0001628280-26-021186.md) | [11.4](/filings/0001628280-25-024434.md) | [12.5](/filings/0001041024-25-000011.md) | [13.6](/filings/0001628280-25-051290.md) | [10.7](/filings/0001628280-26-056461.md) | [9.6](/filings/0001628280-26-031663.md) | [10.5](/filings/0001628280-26-056461.md) |
| Current assets | $m | [28.2](/filings/0001628280-23-038781.md) | [28.8](/filings/0001628280-25-013983.md) | [26.7](/filings/0001628280-24-023056.md) | [29.8](/filings/0001628280-24-035859.md) | [34.2](/filings/0001628280-24-046839.md) | [37.0](/filings/0001628280-26-021186.md) | [33.0](/filings/0001628280-25-024434.md) | [31.6](/filings/0001041024-25-000011.md) | [37.5](/filings/0001628280-25-051290.md) | [38.2](/filings/0001628280-26-056461.md) | [36.9](/filings/0001628280-26-031663.md) | [36.4](/filings/0001628280-26-056461.md) |
| Total assets | $m | [52.6](/filings/0001628280-23-038781.md) | [52.2](/filings/0001628280-25-013983.md) | [50.7](/filings/0001628280-24-023056.md) | [53.0](/filings/0001628280-24-035859.md) | [57.1](/filings/0001628280-24-046839.md) | [59.2](/filings/0001628280-26-021186.md) | [54.0](/filings/0001628280-25-024434.md) | [52.6](/filings/0001041024-25-000011.md) | [57.5](/filings/0001628280-25-051290.md) | [57.1](/filings/0001628280-26-056461.md) | [57.4](/filings/0001628280-26-031663.md) | [56.5](/filings/0001628280-26-056461.md) |
| Current liabilities | $m | [21.4](/filings/0001628280-23-038781.md) | [16.6](/filings/0001628280-25-013983.md) | [14.9](/filings/0001628280-24-023056.md) | [14.9](/filings/0001628280-24-035859.md) | [14.2](/filings/0001628280-24-046839.md) | [14.1](/filings/0001628280-26-021186.md) | [11.2](/filings/0001628280-25-024434.md) | [10.9](/filings/0001041024-25-000011.md) | [9.6](/filings/0001628280-25-051290.md) | [9.6](/filings/0001628280-26-056461.md) | [9.9](/filings/0001628280-26-031663.md) | [11.2](/filings/0001628280-26-056461.md) |
| Total liabilities | $m | [31.1](/filings/0001628280-23-038781.md) | [30.9](/filings/0001628280-25-013983.md) | [30.1](/filings/0001628280-24-023056.md) | [29.5](/filings/0001628280-24-035859.md) | [27.9](/filings/0001628280-24-046839.md) | [26.6](/filings/0001628280-26-021186.md) | [22.4](/filings/0001628280-25-024434.md) | [22.2](/filings/0001041024-25-000011.md) | [20.5](/filings/0001628280-25-051290.md) | [20.2](/filings/0001628280-26-056461.md) | [21.6](/filings/0001628280-26-031663.md) | [21.4](/filings/0001628280-26-056461.md) |
| Long-term debt | $m | [3.3](/filings/0001628280-23-038781.md) | [8.3](/filings/0001628280-25-013983.md) | [8.3](/filings/0001628280-24-023056.md) | [8.3](/filings/0001628280-24-035859.md) | [8.4](/filings/0001628280-24-046839.md) | [8.5](/filings/0001628280-26-021186.md) | [8.6](/filings/0001628280-25-024434.md) | [8.6](/filings/0001041024-25-000011.md) | [8.7](/filings/0001628280-25-051290.md) | [8.8](/filings/0001628280-26-056461.md) | [8.2](/filings/0001628280-26-031663.md) | [7.2](/filings/0001628280-26-056461.md) |
| Current portion of debt | $m | [5.6](/filings/0001628280-23-038781.md) | [0.0](/filings/0001628280-24-012572.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001628280-26-056461.md) | [0.7](/filings/0001628280-26-031663.md) | [1.8](/filings/0001628280-26-056461.md) |
| Shareholders' equity | $m | [21.5](/filings/0001628280-24-046839.md) | [21.3](/filings/0001628280-26-021186.md) | [20.6](/filings/0001628280-25-051290.md) | [23.5](/filings/0001628280-25-051290.md) | [29.1](/filings/0001628280-25-051290.md) | [32.6](/filings/0001628280-26-056461.md) | [31.5](/filings/0001628280-26-056461.md) | [30.4](/filings/0001628280-26-056461.md) | [37.0](/filings/0001628280-25-051290.md) | [37.0](/filings/0001628280-26-056461.md) | [35.9](/filings/0001628280-26-056461.md) | [35.1](/filings/0001628280-26-056461.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(3,753) d](/filings/0001628280-24-046839.md) | [(43.0) d](/filings/0001628280-25-013983.md) | [(2,380)](/filings/0001628280-25-024434.md) | [1,442 d](/filings/0001041024-25-000011.md) | [4,275 d](/filings/0001628280-25-051290.md) | [865 d](/filings/0001628280-26-021186.md) | [(3,487)](/filings/0001628280-26-031663.md) | [1,844 d](/filings/0001628280-26-056461.md) | [(1,307) d](/filings/0001628280-25-051290.md) | [2,291 d](/filings/0001628280-26-021186.md) | [(167)](/filings/0001628280-26-031663.md) | [2,080 d](/filings/0001628280-26-056461.md) |
| Capital expenditure | $k | not reported | [43.0 d](/filings/0001628280-25-013983.md) | [139](/filings/0001628280-25-024434.md) | [286 d](/filings/0001041024-25-000011.md) | [191 d](/filings/0001628280-25-051290.md) | [395 d](/filings/0001628280-26-021186.md) | [63.0](/filings/0001628280-26-031663.md) | [164 d](/filings/0001628280-26-056461.md) | [229 d](/filings/0001628280-25-051290.md) | [86.0 d](/filings/0001628280-26-021186.md) | [425](/filings/0001628280-26-031663.md) | [617 d](/filings/0001628280-26-056461.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [18.5](/filings/0001628280-23-038781.md) | [18.4](/filings/0001628280-24-023056.md) | [18.5](/filings/0001628280-24-035859.md) | [27.5](/filings/0001628280-24-046839.md) | [29.3](/filings/0001628280-25-024434.md) | [32.0](/filings/0001041024-25-000011.md) | [32.4](/filings/0001628280-25-051290.md) | [34.1](/filings/0001628280-26-031663.md) | [3.4](/filings/0001628280-26-056461.md) | [36.0](/filings/0001628280-25-051290.md) | [39.4](/filings/0001628280-26-031663.md) | [4.0](/filings/0001628280-26-056461.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 4,030,465 at 2026-08-10, from the cover of the [10-Q filed 2026-08-13](/filings/0001628280-26-056461.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:31 ET. No prices; not investment advice.